Quarterly ResultAug 11, 2026, 08:22 AM
Veradermics Reports Positive Phase 2 Results; Q2 Net Loss $23.5M
AI Summary
Veradermics, Inc. reported a net loss of $23.5 million for the second quarter ended June 30, 2026, compared to a net loss of $15.6 million in the prior year. The company announced positive topline results from its open-label Phase 2 Study '207' for VDPHL01 in female pattern hair loss, demonstrating rapid onset and consistent hair growth. Veradermics also completed patient enrollment for the registration-directed Phase 2/3 Study '306' and expects multiple data milestones for male pattern hair loss trials in 2H26. The company maintains a strong cash position of $819.9 million, expected to fund operations into 2030.
Key Highlights
- Positive topline results from Phase 2 Study '207' for VDPHL01 in female pattern hair loss.
- VDPHL01 demonstrated mean increase in non-vellus TAHC of 22.7-23.3 hairs/cm² at Month 6.
- Completed patient enrollment for Phase 2/3 Study '306' (556 participants); topline data expected 1H27.
- Anticipated topline data from confirmatory Phase 3 Study '304' (male pattern hair loss) in 2H26.
- Cash, cash equivalents, and marketable securities totaled $819.9 million as of June 30, 2026.
- Net loss for Q2 2026 was $23.5 million, compared to $15.6 million in Q2 2025.
- R&D expenses increased to $18.6 million in Q2 2026 from $14.3 million in Q2 2025.
- G&A expenses increased to $10.9 million in Q2 2026 from $1.7 million in Q2 2025.
Price Impact
More from MANE